Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Therapeutic drug monitoring (TDM), which involves measurement of drug or active
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of
rheumatic diseases since their incorporation into treatment protocols two decades ago …

Abstract Background and Aims Therapeutic drug monitoring [TDM] has proven to be
effective for optimising anti-tumour necrosis factor [TNF] therapy in inflammatory bowel …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Background Proactive testing of adalimumab serum levels is debated. Aim To study the
association between adalimumab serum levels at week 4 and the development of anti …

OBJECTIVES: Adalimumab is usually self-injected at home, making prospective serial-
sampling studies challenging and scarce. This has led to a gap in knowledge about …